NAT2 and Absence of circulating granulocytes: Although pharmacogenetic testing was not performed in this case, genome-wide studies have identified associations between metamizole-induced agranulocytosis and polymorphisms in HLA-B*27:05, NAT2, and cytochrome P450 isoenzymes [6].